Value of panel reactive antibodies (PRA) as a guide to the treatment of hyperimmunized patients in renal transplantation

Transpl Int. 1992:5 Suppl 1:S54-7. doi: 10.1007/978-3-642-77423-2_17.

Abstract

Patient presensitization represents a considerable problem in candidacy for renal transplantation. While it is well known that hyperimmunized patients--panel reactive antibody (PRA) higher than 60%--create difficulties in donor matching and have a worse outcome than non-hyperimmunized patients, less information is available on patients with an intermediate degree of sensitization (30-60%). In order to evaluate how graft outcome relates to such degrees of sensitization, 241 consecutive transplanted patients were divided into two groups on the basis of their previous year's PRA peak: group A, PRA 0-29%; group B, PRA 30-60%. Group A showed a significantly better survival both in the first year (90% vs 79%, P < 0.05) and in the third year (82% vs 64%, P < 0.01). However, detailed analysis of group B demonstrated that some parameters may significantly influence graft outcome: (1) better compatibility on locus DR; (2) a primary kidney transplant; (3) a dialysis duration of less than 6 months; and (4) the prophylactic use of antilymphocyte globulin (ALG).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antilymphocyte Serum / therapeutic use
  • Blood Transfusion
  • Child
  • Child, Preschool
  • Cytotoxicity, Immunologic
  • Female
  • Follow-Up Studies
  • Graft Survival / immunology
  • Histocompatibility Testing
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Infant
  • Isoantibodies / blood*
  • Kidney Transplantation / immunology*
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Renal Dialysis
  • Reoperation
  • Retrospective Studies
  • Time Factors

Substances

  • Antilymphocyte Serum
  • Immunosuppressive Agents
  • Isoantibodies